{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:19:17Z","timestamp":1793143157529,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001136","name":"Australian and New Zealand College of Anaesthetists","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001136","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015539","name":"Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015539","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001161","name":"Australian Society of Anaesthetists","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001161","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bjanaesthesia.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["British Journal of Anaesthesia"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.bja.2025.05.036","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T03:45:59Z","timestamp":1754451959000},"page":"594-607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Impact of genetic variations on the pharmacokinetics, dose requirements, and clinical effects of propofol: a systematic review"],"prefix":"10.1016","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0492-5006","authenticated-orcid":false,"given":"Michelle D.","family":"Gerstman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6393-0675","authenticated-orcid":false,"given":"Raymond K.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6705-6004","authenticated-orcid":false,"given":"Kwok M.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl M.J.","family":"Kirkpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Riedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4779-0380","authenticated-orcid":false,"given":"Andrew A.","family":"Somogyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bja.2025.05.036_bib1","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s40262-018-0672-3","article-title":"Clinical pharmacokinetics and pharmacodynamics of propofol","volume":"57","author":"Sahinovic","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bja.2025.05.036_bib2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0300-483X(02)00449-3","article-title":"Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance","volume":"181\u2013182","author":"Miners","year":"2002","journal-title":"Toxicology"},{"key":"10.1016\/j.bja.2025.05.036_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082562","article-title":"Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy","volume":"8","author":"Preissner","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bja.2025.05.036_bib4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/03602530902843483","article-title":"Polymorphism of human cytochrome P450 enzymes and its clinical impact","volume":"41","author":"Zhou","year":"2009","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.bja.2025.05.036_bib5","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1038\/srep02161","article-title":"A practical method to detect SNVs and indels from whole genome and exome sequencing data","volume":"3","author":"Shigemizu","year":"2013","journal-title":"Sci Rep"},{"key":"10.1016\/j.bja.2025.05.036_bib6","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/cpt.1322","article-title":"Standardized biogeographic grouping system for annotating populations in pharmacogenetic research","volume":"105","author":"Huddart","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bja.2025.05.036_bib7","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2217\/14622416.8.9.1127","article-title":"C-440T\/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation","volume":"8","author":"Baldelli","year":"2007","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.bja.2025.05.036_bib8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1124\/jpet.103.054072","article-title":"Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs","volume":"307","author":"Villeneuve","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bja.2025.05.036_bib9","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/sj.clpt.6100073","article-title":"The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers","volume":"81","author":"L\u00e9vesque","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bja.2025.05.036_bib10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s13353-016-0373-2","article-title":"The effect of UGT1A9, CYP2B6 and CYP2C9 genes polymorphism on individual differences in propofol pharmacokinetics among Polish patients undergoing general anaesthesia","volume":"58","author":"Mikstacki","year":"2017","journal-title":"J Appl Genet"},{"key":"10.1016\/j.bja.2025.05.036_bib11","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/aps.2015.7","article-title":"Associations of UDP-glucuronosyltransferases polymorphisms with mycophenolate mofetil pharmacokinetics in Chinese renal transplant patients","volume":"36","author":"Xie","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.bja.2025.05.036_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2023\/8283470","article-title":"Allelic and genotype frequencies of CYP2B6(\u2217)2 (64C > T) and CYP2B6(\u2217)3 (777C > A) in three dominant ethnicities of the Iranian population","volume":"2023","author":"Khavandegar","year":"2023","journal-title":"Genet Res (Camb)"},{"key":"10.1016\/j.bja.2025.05.036_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.692234","article-title":"CYP2B6 functional variability in drug metabolism and exposure across populations-implication for drug safety, dosing, and individualized therapy","volume":"12","author":"Langmia","year":"2021","journal-title":"Front Genet"},{"key":"10.1016\/j.bja.2025.05.036_bib15","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1007\/s11033-014-3256-9","article-title":"Allele and genotype frequencies of CYP2B6 in a Turkish population","volume":"41","author":"Yuce-Artun","year":"2014","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.bja.2025.05.036_bib16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/cpt.2166","article-title":"PharmVar GeneFocus: CYP2B6","volume":"110","author":"Desta","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bja.2025.05.036_bib17","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study","volume":"18","author":"Haas","year":"2004","journal-title":"Aids"},{"key":"10.1016\/j.bja.2025.05.036_bib18","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41397-019-0112-2","article-title":"Meta-analysis of the associations of CYP2B6-516G>T polymorphisms with efavirenz-induced central nervous system side effects and virological outcome in HIV-infected adults","volume":"20","author":"Cheng","year":"2020","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.bja.2025.05.036_bib19","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/cpt.3338","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2B6 genotype and methadone therapy","volume":"116","author":"Robinson","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bja.2025.05.036_bib20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/cpt.1830","article-title":"Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs","volume":"108","author":"Theken","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bja.2025.05.036_bib21","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/FPC.0b013e3283349e84","article-title":"Cytochrome P450 2C9-CYP2C9","volume":"20","author":"Van Booven","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.bja.2025.05.036_bib22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40246-023-00461-z","article-title":"Global distribution of functionally important CYP2C9 alleles and their inferred metabolic consequences","volume":"17","author":"Zhou","year":"2023","journal-title":"Hum Genomics"},{"key":"10.1016\/j.bja.2025.05.036_bib23","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/cpt.2149","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy","volume":"110","author":"Crews","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bja.2025.05.036_bib24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00702-018-1922-0","article-title":"An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes","volume":"126","author":"Mostafa","year":"2019","journal-title":"J Neural Transm (Vienna)"},{"key":"10.1016\/j.bja.2025.05.036_bib25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/bja\/aep143","article-title":"Pharmacokinetic models for propofol\u2014defining and illuminating the devil in the detail","volume":"103","author":"Absalom","year":"2009","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2025.05.036_bib26","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.bja.2018.01.018","article-title":"Pharmacokinetic\u2013pharmacodynamic model for propofol for broad application in anaesthesia and sedation","volume":"120","author":"Eleveld","year":"2018","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2025.05.036_bib27","first-page":"2065","article-title":"Schnider and Eleveld models for propofol target-controlled infusion anesthesia: a clinical comparison","volume":"13","author":"Linassi","year":"2023","journal-title":"Life (Basel)"},{"key":"10.1016\/j.bja.2025.05.036_bib28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2044.1998.53s104.x","article-title":"Evaluation of the predictive performance of a \u2018Diprifusor\u2019 TCI system","volume":"53","author":"Swinhoe","year":"1998","journal-title":"Anaesthesia"},{"key":"10.1016\/j.bja.2025.05.036_bib29","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1399-6576.1993.tb03746.x","article-title":"Effective concentration 50 for propofol with and without 67% nitrous oxide","volume":"37","author":"Davidson","year":"1993","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.bja.2025.05.036_bib30","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1016\/j.bja.2019.10.019","article-title":"Retrospective comparison of Eleveld, Marsh, and Schnider propofol pharmacokinetic models in 50 patients","volume":"124","author":"H\u00fcppe","year":"2020","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2025.05.036_bib31","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.bja.2025.05.036_bib32","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.bja.2025.05.036_bib33","doi-asserted-by":"crossref","first-page":"532","DOI":"10.2133\/dmpk.DMPK-11-RG-039","article-title":"Individual differences in pharmacokinetics and pharmacodynamics of anesthetic agent propofol with regard to CYP2B6 and UGT1A9 genotype and patient age","volume":"26","author":"Kansaku","year":"2011","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.bja.2025.05.036_bib34","doi-asserted-by":"crossref","first-page":"597","DOI":"10.22237\/jmasm\/1257035100","article-title":"New effect size rules of thumb","volume":"8","author":"Sawilowsky","year":"2009","journal-title":"J Modern Appl Stat Methods"},{"key":"10.1016\/j.bja.2025.05.036_bib35","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"2013"},{"key":"10.1016\/j.bja.2025.05.036_bib36","series-title":"Practical meta-analysis effect size calculator (version 2023.11. 27)","author":"Wilson","year":"2023"},{"key":"10.1016\/j.bja.2025.05.036_bib37","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13643-023-02217-1","article-title":"Ten circumstances and solutions for finding the sample mean and standard deviation for meta-analysis","volume":"12","author":"Chi","year":"2023","journal-title":"Systematic Reviews"},{"key":"10.1016\/j.bja.2025.05.036_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15657-2","article-title":"Longrange PCR-based next-generation sequencing in pharmacokinetics and pharmacodynamics study of propofol among patients under general anaesthesia","volume":"7","author":"Zakerska-Banaszak","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.bja.2025.05.036_bib39","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1017\/S0265021507000476","article-title":"An investigation of potential genetic determinants of propofol requirements and recovery from anaesthesia","volume":"24","author":"Iohom","year":"2007","journal-title":"Eur J Anaesthesiol"},{"key":"10.1016\/j.bja.2025.05.036_bib40","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/bcpt.12070","article-title":"Sex difference in formation of propofol metabolites: a replication study","volume":"113","author":"Choong","year":"2013","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.bja.2025.05.036_bib41","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/bcpt.12277","article-title":"Pharmacogenetics, plasma concentrations, clinical signs and EEG during propofol treatment","volume":"115","author":"Khan","year":"2014","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.bja.2025.05.036_bib42","doi-asserted-by":"crossref","first-page":"183","DOI":"10.17264\/stmarieng.6.183","article-title":"Effects of genetic polymorphism of CYP2B6 and UGT1A9 and sex differences on pharmacokinetics of propofol","volume":"6","author":"Kobayashi","year":"2015","journal-title":"J St Marianna Univ"},{"key":"10.1016\/j.bja.2025.05.036_bib43","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3923\/ijp.2016.401.407","article-title":"UGT1A9 single nucleotide polymorphisms do not account for the variability of response to propofol: a one-way design with multiple levels study of the propofol pharmacodynamics","volume":"12","author":"Tian","year":"2016","journal-title":"Int J Pharmacol"},{"key":"10.1016\/j.bja.2025.05.036_bib44","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20170722","article-title":"Relationship between UGT1A9 gene polymorphisms, efficacy, and safety of propofol in induced abortions amongst Chinese population: a population-based study","volume":"37","author":"Wang","year":"2017","journal-title":"Biosci Rep"},{"key":"10.1016\/j.bja.2025.05.036_bib45","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40981-018-0196-8","article-title":"Effect of sex and polymorphisms of CYP2B6 and UGT1A9 on the difference between the target-controlled infusion predicted and measured plasma propofol concentration","volume":"4","author":"Fujita","year":"2018","journal-title":"JA Clin Rep"},{"key":"10.1016\/j.bja.2025.05.036_bib46","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2478\/bjmg-2020-0030","article-title":"Influence of potential gene polymorphisms on propofol dosage regimen in patients undergoing abdominal hysterectomy","volume":"23","author":"Ivanov","year":"2020","journal-title":"Balkan J Med Genet"},{"key":"10.1016\/j.bja.2025.05.036_bib47","first-page":"13","article-title":"The effect of UGT1A9, CYP2B6 and CYP2C9 genes polymorphism on propofol pharmacokinetics in children","volume":"13","author":"Pavlovic","year":"2020","journal-title":"Pharmgenom Pers Med"},{"key":"10.1016\/j.bja.2025.05.036_bib48","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/postgradmedj-2021-141375","article-title":"Effect of CYB2B6 (c.516G>T), CYP2C9 (c.1075A>C) and UGT1A9 (c.98T>C) polymorphisms on propofol pharmacokinetics in patients submitted to colonoscopy: a cohort study","volume":"99","author":"Poma","year":"2023","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.bja.2025.05.036_bib49","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41397-021-00263-3","article-title":"A single nucleotide polymorphism-based formula to predict the risk of propofol TCI concentration being over 4 microg mL(-1) at the time of loss of consciousness","volume":"22","author":"Zheng","year":"2022","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.bja.2025.05.036_bib50","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/bcp.15480","article-title":"Nongenetic and genetic predictors of haemodynamic instability induced by propofol and opioids: a retrospective clinical study","volume":"89","author":"Gu","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bja.2025.05.036_bib51","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s43440-023-00455-7","article-title":"Effect of common OPRM1, COMT, SLC6A4, ABCB1, and CYP2B6 polymorphisms on perioperative analgesic and propofol demands on patients subjected to thyroidectomy surgery","volume":"75","author":"Soultati","year":"2023","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.bja.2025.05.036_bib52","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14622416.2024.2344430","article-title":"Influence of genetic polymorphisms on pharmacokinetics and treatment response of mycophenolic acid: a scoping review","volume":"25","author":"Yow","year":"2024","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.bja.2025.05.036_bib53","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6852857","article-title":"Metabolic profiles of propofol and fospropofol: clinical and forensic interpretative aspects","volume":"2018","author":"Dinis-Oliveira","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.bja.2025.05.036_bib54","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2125.2005.02393.x","article-title":"Kidneys contribute to the extrahepatic clearance of propofol in humans, but not lungs and brain","volume":"60","author":"Hiraoka","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bja.2025.05.036_bib55","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/cpt.2321","article-title":"Pharmacogene variation consortium: a global resource and repository for pharmacogene variation","volume":"110","author":"Gaedigk","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bja.2025.05.036_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1180487","article-title":"Editorial: pharmacogenomics and ethnicity: prevalence and clinical significance of pharmacogenomic biomarkers in indigenous and other populations","volume":"14","author":"Patrinos","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bja.2025.05.036_bib57","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2217\/pgs-2018-0085","article-title":"Clinical and pharmacogenetics associated with recovery time from general anesthesia","volume":"19","author":"Xie","year":"2018","journal-title":"Pharmacogenomics"}],"container-title":["British Journal of Anaesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007091225003502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007091225003502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T02:57:06Z","timestamp":1788231426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007091225003502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0007091225003502"],"URL":"https:\/\/doi.org\/10.1016\/j.bja.2025.05.036","relation":{},"ISSN":["0007-0912"],"issn-type":[{"value":"0007-0912","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of genetic variations on the pharmacokinetics, dose requirements, and clinical effects of propofol: a systematic review","name":"articletitle","label":"Article Title"},{"value":"British Journal of Anaesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bja.2025.05.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2025 Published by Elsevier Ltd on behalf of British Journal of Anaesthesia.","name":"copyright","label":"Copyright"}]}}